3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

In the 3-year assessment of the SCALE Obesity and Prediabetes trial the researchers aimed to evaluate the proportion of individuals with prediabetes who were diagnosed with type 2 diabetes.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

Time to diabetes onset by 160 weeks was the primary outcome, evaluated in all randomised treated individuals with at least one post-baseline assessment.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.

The trial was conducted at 191 clinical research sites in 27 countries and is registered with ClinicalTrials.gov, number NCT01272219.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents and Incretins.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2017 (Lancet (London, England)), a journal based in England.

More context: the Liraglutide compound page.